Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04052594 | A Study of LY3475766 in Healthy Participants | PHASE1 | COMPLETED | 48 | — | — | Sep 3, 2019 | Mar 31, 2021 | Apr 28, 2021 | 4 | United States |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3475766 - IV | EXPERIMENTAL | LY3475766 administered intravenously (IV) to participants with dyslipidemia |
| Placebo - IV | PLACEBO_COMPARATOR | Placebo administered IV to participants with dyslipidemia |
| LY3475766 - SC | EXPERIMENTAL | LY3475766 administered subcutaneously (SC) to participants with dyslipidemia |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC to participants with dyslipidemia |
| Name | Type | Description |
|---|---|---|
| LY3475766 - IV | DRUG | Administered IV |
| LY3475766 - SC | DRUG | Administered SC |
| Placebo - IV | DRUG | Administered IV |
| Placebo - SC | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy males or females, apart from dyslipidemia * Male participants must agree to adhere to contraception restrictions * Female participants must be of nonchildbearing potential and include those who are infertile due to surgical sterilization or those who are po...